Apolipoprotein E genotype and progression of Alzheimer's disease: The Rotterdam Study

Arjen J.C. Slooter; Jeanine J. Houwing-Duistermaat; Frans Van Harskamp; Marc Cruts; Christine Van Broeckhoven; Monique M.B. Breteler; Albert Hofman; Theo Stijnen; Cornelia M. Van Duijn

doi:10.1007/s004150050351

Apolipoprotein E genotype and progression of Alzheimer's disease: The Rotterdam Study

Arjen J.C. Slooter^*, Jeanine J. Houwing-Duistermaat, Frans Van Harskamp, Marc Cruts, Christine Van Broeckhoven, Monique M.B. Breteler, Albert Hofman, Theo Stijnen, Cornelia M. Van Duijn

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

45 Citations (Scopus)

Abstract

The APOE*4 allele of the apolipoprotein E gene increases the risk of Alzheimer's disease (AD), but whether it also affects the course of the disease is controversial. However, all studies on this issue until now have been based on patients at various stages of disease. In the present population-based study, 97 patients were included at a similar stage, i.e., before the onset of symptoms, and followed for up to 5 years. We found that the APOE*4 allele is not a strong determinant of survival in AD. As change in cognitive function and severity of dementia are similar for AD patients with and without APOE*4, our study suggests that progression of AD is not related to the APOE*4 allele.

Original language	English
Pages (from-to)	304-308
Number of pages	5
Journal	Journal of Neurology
Volume	246
Issue number	4
DOIs	https://doi.org/10.1007/s004150050351
Publication status	Published - 26 May 1999
Externally published	Yes

Keywords

Alzheimer's disease
Apolipoprotein E
Progression
Survival

Access to Document

10.1007/s004150050351

Cite this

@article{1b4db4f5b56a4efda4a4199bb93b6eef,

title = "Apolipoprotein E genotype and progression of Alzheimer's disease: The Rotterdam Study",

abstract = "The APOE*4 allele of the apolipoprotein E gene increases the risk of Alzheimer's disease (AD), but whether it also affects the course of the disease is controversial. However, all studies on this issue until now have been based on patients at various stages of disease. In the present population-based study, 97 patients were included at a similar stage, i.e., before the onset of symptoms, and followed for up to 5 years. We found that the APOE*4 allele is not a strong determinant of survival in AD. As change in cognitive function and severity of dementia are similar for AD patients with and without APOE*4, our study suggests that progression of AD is not related to the APOE*4 allele.",

keywords = "Alzheimer's disease, Apolipoprotein E, Progression, Survival",

author = "Slooter, {Arjen J.C.} and Houwing-Duistermaat, {Jeanine J.} and {Van Harskamp}, Frans and Marc Cruts and {Van Broeckhoven}, Christine and Breteler, {Monique M.B.} and Albert Hofman and Theo Stijnen and {Van Duijn}, {Cornelia M.}",

year = "1999",

month = may,

day = "26",

doi = "10.1007/s004150050351",

language = "English",

volume = "246",

pages = "304--308",

journal = "Journal of Neurology",

issn = "0340-5354",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "4",

}

TY - JOUR

T1 - Apolipoprotein E genotype and progression of Alzheimer's disease

T2 - The Rotterdam Study

AU - Slooter, Arjen J.C.

AU - Houwing-Duistermaat, Jeanine J.

AU - Van Harskamp, Frans

AU - Cruts, Marc

AU - Van Broeckhoven, Christine

AU - Breteler, Monique M.B.

AU - Hofman, Albert

AU - Stijnen, Theo

AU - Van Duijn, Cornelia M.

PY - 1999/5/26

Y1 - 1999/5/26

N2 - The APOE*4 allele of the apolipoprotein E gene increases the risk of Alzheimer's disease (AD), but whether it also affects the course of the disease is controversial. However, all studies on this issue until now have been based on patients at various stages of disease. In the present population-based study, 97 patients were included at a similar stage, i.e., before the onset of symptoms, and followed for up to 5 years. We found that the APOE*4 allele is not a strong determinant of survival in AD. As change in cognitive function and severity of dementia are similar for AD patients with and without APOE*4, our study suggests that progression of AD is not related to the APOE*4 allele.

AB - The APOE*4 allele of the apolipoprotein E gene increases the risk of Alzheimer's disease (AD), but whether it also affects the course of the disease is controversial. However, all studies on this issue until now have been based on patients at various stages of disease. In the present population-based study, 97 patients were included at a similar stage, i.e., before the onset of symptoms, and followed for up to 5 years. We found that the APOE*4 allele is not a strong determinant of survival in AD. As change in cognitive function and severity of dementia are similar for AD patients with and without APOE*4, our study suggests that progression of AD is not related to the APOE*4 allele.

KW - Alzheimer's disease

KW - Apolipoprotein E

KW - Progression

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0032925059&partnerID=8YFLogxK

U2 - 10.1007/s004150050351

DO - 10.1007/s004150050351

M3 - Article

C2 - 10367700

AN - SCOPUS:0032925059

SN - 0340-5354

VL - 246

SP - 304

EP - 308

JO - Journal of Neurology

JF - Journal of Neurology

IS - 4

ER -

Apolipoprotein E genotype and progression of Alzheimer's disease: The Rotterdam Study

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this